Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

Trial Profile

A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Triptorelin (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Immune System Regulation
  • Most Recent Events

    • 01 Feb 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Oct 2019.
    • 20 Sep 2018 According to ISR Immune System Regulation Holding media release, the first patient is now enrolled in this study. The study is expected to be ending in Q2 2019.
    • 19 Sep 2018 Planned End Date changed from 1 May 2019 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top